According to a recently published report, the Global Angiotensin Converting Enzyme (ACE) Market is expected to deplete at the CAGR of – 0.6% during 2017-2025. The global angiotensin converting enzyme (ACE) is segmented on the basis of application, drug, and geography. The report on global angiotensin converting enzyme (ACE) market forecast 2017-2025 (by drugs, applications, and geography) provides a detailed overview and predictive analysis of the market.
Full report available Global Angiotensin Converting Enzyme (ACE) Market 2017 – 2025 (by drugs, applications, and geography) report at http://www.briskinsights.com/report/angiotensin-converting-enzyme-ace-inhibitors-market
ACE inhibitors is responsible for blocking the conversion of angiotensin I to angiotensin II, used in the treatment of hypertension and congestive heart failure. The global statistics published by the World Health Organization (WHO) suggests that globally cardiovascular disease is responsible for approximately 17 million deaths a year, nearly one third of the total. Out of these deaths, complications of hypertension account for 9.4 million deaths worldwide every year. ACE inhibitors market can be segmented on the basis of type of drug and application. The type of drug segment comprises of benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and combination ACE inhibitors. The key applications of ACE inhibitors comprises hypertension, coronary artery disease, heart failure, myocardial infarction, diabetes, chronic kidney disorders, and others (scleroderma, migraine, and others). It was observed that around 40% of the market share was owned by hypertension due to rising prevalence of hypertension, high efficacy of ACE inhibitors in hypertension treatment. The geographical segmentation comprises regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. North America accounted for the largest market share due to key market driving factors such as rising prevalence of cardiovascular and kidney diseases, peaking obesity in the population due to sedentary lifestyle, and supportive reimbursement policies. The other factors responsible for North America’s domination are developed healthcare infrastructure, and high public awareness related to diagnosis, treatment and management of lifestyle diseases.
Scope of the report
1. Global Angiotensin Converting Enzyme (ACE) Market, By Drug Type, 2015–2025 ($ Millon)
1.11. Combination ACE Inhibitors
Browse Here For Full Report : http://www.briskinsights.com/report/angiotensin-converting-enzyme-ace-inhibitors-market
2. Global Angiotensin Converting Enzyme (ACE) Market, By Application, 2015-2025 ($ Millon)
2.2. Coronary Artery Diseases
2.3. Heart Failure
2.4. Myocardial Infarction
2.6. Chronic Kidney Disorders
2.7. Others (Scleroderma, Migraine and others)
3. Global Apheresis Equipment Market, By Geography, 2015-2025 ($ Millon)
3.1. North America
3.3. Asia Pacific
3.4. Latin America (LATAM)
3.5. Middle East and Africa (MEA)
4. Company Profiles
4.1. Abbott Laboratories
4.2. Pfizer, Inc.
4.3. Novartis AG
4.4. Merck & Co.
4.5. Astra Zeneca plc
4.6. Jhonson and Johnson Limited
4.7. Eli Lilly and Company
4.8. Sanofi SA
4.9. Bristol-Myers Squibb Company
4.10. Bayer AG
4.11. GlaxoSmithKline plc
4.12. Teva Pharmaceutical Industries Ltd.
4.13. Other Notable Players
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Our team of 200 analysts’ provides enterprises with strategic insights. Brisk Insights works to help enterprises grow through strategic insights and actionable solutions
Download Free Request Sample: http://www.briskinsights.com/sample-request/482
Company Name: Brisk Insights
Contact Person: Jennifer Smith
Address:Office 1094, 109 Vernon House, Friar Lane, Nottingham NG1 6DQ
Country: United Kingdom